|Bid||103.83 x 800|
|Ask||103.92 x 800|
|Day's Range||102.54 - 104.52|
|52 Week Range||76.93 - 121.23|
|Beta (3Y Monthly)||0.88|
|PE Ratio (TTM)||13.18|
|Earnings Date||May 15, 2019 - May 20, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||101.16|
Mid-caps stocks, like Taro Pharmaceutical Industries Ltd. (NYSE:TARO) with a market capitalization of US$4.1b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-cap stocks...
Taro Pharmaceutical Industries Ltd NYSE:TAROView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for TARO with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting TARO. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding TARO are favorable, with net inflows of $923 million. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Zacks.com featured expert Kevin Matras highlights: Unilever, Rent-A-Center, Abercrombie & Fitch, Taro Pharmaceutical and PCTEL
While not a mind-blowing move, it is good to see that the Taro Pharmaceutical Industries Ltd. (NYSE:TARO) share price has gained 19% in the last three months. But that cannotRead More...
Taro Pharmaceutical Industries Ltd. (TARO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Zacks.com featured highlights include: Taro, Anglo American, eGain, Korea Electric and Grupo Aeroportuario
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 6) Array Biopharma Inc (NASDAQ: ARRY ) Millendo Therapeutics ...
Taro (TARO) delivered earnings and revenue surprises of 23.08% and 0.96%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The Haifa Bay, Israel-based company said it had net income of $2.40 per share. The drug maker posted revenue of $176.4 million in the period. Taro shares have risen 10 percent since the beginning of the ...
Taro Pharmaceutical Industries Ltd. today provided unaudited financial results for the three and nine months ended December 31, 2018.
Taro Pharmaceutical Industries Ltd. announced today that it plans to release its financial results for the quarter ended December 31, 2018, after the close of market on Wednesday, February 6, 2019.
Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...
Taro Pharmaceutical Industries Ltd. announced today that it has completed its $250 million share repurchase program. The company bought back 2,493,378 of its ordinary shares in open market transactions at an average price of $100.28 per share.
Hedge funds and other investment firms run by legendary investors like Israel Englander and Ray Dalio are entrusted to manage billions of dollars of accredited investors’ money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to invest a […]